Bone tumour
giant cell tumour bone X-ray radiograph

This diagnostic X-ray radiograph demonstrates a post-surgical resection arthrodesis of a long bone, typically the femur or tibia, following treatment for a giant cell tumor. The image shows a long, radio-opaque intramedullary (IM) nail spanning the medullary canal to provide structural stability. Two transverse interlocking screws are visible, securing the nail to the cortical bone. A distinct black arrow points to a localized radiolucent gap between the bone segments, signifying a nonunion of the bone graft at the 1.5-year postoperative follow-up. The surrounding bone shows irregular contours and variable density, indicating unsuccessful bony bridging and attempted remodeling at the graft-host interface. This visual serves as a clinical example of a complication in limb-salvage surgery and the failure of secondary arthrodesis using IM fixation.

Multi-modal diagnostic imaging sequence (X-ray, MRI, CT) illustrating a Giant Cell Tumor of Bone (GCTB) in the distal femur and its postoperative progression. Top row: (a) Plain radiograph showing an ill-defined osteolytic lesion in the distal femoral metaphysis; (b) T1-weighted MRI showing a homogenous low-signal intensity mass; (c) T2-weighted fat-suppressed MRI showing heterogeneous intermediate-to-high signal intensity. Middle row: (d) Postoperative radiograph and (e, f) coronal/sagittal CT scans at 1 month showing the curetted cavity filled with radiopaque beta-tricalcium phosphate (β-TCP) blocks and surrounding granular particles. Bottom row: (g) Radiograph and (h, i) CT scans at 13 months post-operation demonstrating local recurrence characterized by new osteolysis predominantly within the β-TCP blocks and adjacent thinning of the cortical bone. This sequence serves as a clinical case study for evaluating bone substitute integration versus tumor recurrence using longitudinal multi-modal imaging.

This comparative x-ray study displays two anterior-posterior radiographs of a human left hip joint, illustrating the progression of Tenosynovial Giant Cell Tumor (TSGCT) effects and subsequent post-surgical changes. Radiograph A (initial examination) shows clear osteolytic lesions at the femoral head-neck junction, indicated by black arrowheads; these appear as radiolucent, irregular areas of bone destruction, though the joint space and articular surfaces remain relatively preserved. Radiograph B shows the same hip three years after tumor resection. This follow-up image demonstrates secondary osteoarthritic changes, highlighted by black arrows, including joint space narrowing, subchondral sclerosis, and marginal osteophyte formation (bone spurs) at the superior acetabular and femoral margins. A prominent surgical screw is visible crossing the femoral neck into the head, indicating orthopedic stabilization following the tumor excision. This comparison highlights the clinical challenge of secondary joint degeneration following the management of intra-articular neoplastic processes.

A series of four diagnostic x-ray radiographs documenting the management of a giant cell tumor (GCT) of the distal femur. (a, b) Pre-operative anteroposterior and lateral views showing a large, osteolytic lesion in the distal femoral metaphysis with associated cortical thinning and a pathological fracture, resulting in significant joint misalignment. (c) Immediate post-operative radiograph demonstrating surgical reconstruction following intralesional curettage. The reconstruction utilizes internal fixation with multiple orthopedic screws and cerclage wires alongside bone grafting (fibula struts) to stabilize the fracture site and restore anatomical alignment. (d) Two-year post-operative radiograph showing advanced bone healing and remodeling. There is significant graft consolidation and restoration of the distal femoral shape and bone density. The joint space is maintained, and hardware remains in situ with no evidence of tumor recurrence or subchondral collapse. This sequence illustrates a successful orthopedic oncology intervention for aggressive benign bone tumors complicated by fracture.
"giant cell tumor" bone
| Feature | Details |
|---|---|
| Nature | Locally aggressive benign tumour (can rarely metastasize) |
| Age | 20-40 years (80% of cases between 18-45 years) |
| Sex | Slight female predominance (M:F = 2:3) |
| Incidence | ~5% of all bone neoplasms; ~20% of benign bone tumours |
| Common sites | Distal femur > proximal tibia > distal radius (knee = 55% of cases) |
| Location within bone | Epiphysis (subarticular/subchondral), eccentric |
This explains why denosumab (a RANKL inhibitor) works - it targets the driver of osteoclast activity.



| Stage | Description |
|---|---|
| Stage 1 (Latent) | Inactive, well-defined margin with intact cortex |
| Stage 2 (Active) | Expanded, thin cortex but intact |
| Stage 3 (Aggressive) | Cortical destruction, soft-tissue extension |
| Point | Fact |
|---|---|
| Neoplastic cell | Mononuclear stromal cell (osteoblast precursor) |
| Key molecule | RANKL (drives osteoclast formation) |
| Drug target | Denosumab (RANKL inhibitor) |
| Most common site | Distal femur > proximal tibia |
| Location in bone | Epiphysis (eccentric, subarticular) |
| X-ray | Purely lytic, eccentric, no sclerotic rim, no matrix |
| Histology key | Nuclei of mononuclear cells = nuclei of giant cells |
| Local recurrence after curettage | 40-60% |
| Lung metastases | ~3-4% (benign behaviour) |
| Malignant transformation | <10%; osteosarcoma most common |
| Benign but locally aggressive | Yes - can still spread to lungs |